Cargando…

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS

Detalles Bibliográficos
Autores principales:	WILLIAMS, STEPHANIE N, WALO JR, RICHARD, LATTANZIO, NATALIA, DAWKINS, KEVIN, K ABDELAL, QASSEM, HAMAD, KAREN, WIESE-ROMETSCH, WILHELMINE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:	Critical Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548756/ http://dx.doi.org/10.1016/j.chest.2022.08.707

Ejemplares similares

A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge
por: Bell, Stephen, et al.
Publicado: (2021)

SAT-593 Thyrotoxic Heart Disease: Rare but Serious Manifestation of Congestive Heart Failure
por: Petrenko, Olesya, et al.
Publicado: (2019)

Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
por: Lattanzio, Natalia, et al.
Publicado: (2021)

Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection
por: Lorenzo, Christian J., et al.
Publicado: (2020)

COMPARATIVE EFFECTIVENESS OF INHALED NITRIC OXIDE IN ARDS AND VIRAL PNEUMONIA WITH AND WITHOUT COVID-19
por: JR, RICHARD WALO, et al.
Publicado: (2022)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

Heart failure ejection fraction class conversions: impact of biomarkers, co‐morbidities, and pharmacotherapy
por: Lorenzo, Christian J., et al.
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
por: Izumo, Takehiro, et al.
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

A case report of disseminated herpes simplex hepatitis masquerading as spinal headache
por: Lattanzio, Natalia, et al.
Publicado: (2020)

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
por: Yasuda, Yuto, et al.
Publicado: (2022)

Using Objective Electrocardiographic Data To Better Predict Mortality In Patients Hospitalized With COVID-19
por: Malik, Bobby, et al.
Publicado: (2023)

Presentation Traits Of Vaccinated Versus Unvaccinated Heart Failure Patients At Acute Covid-19 Hospitalization
por: Burns, Katherine, et al.
Publicado: (2023)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy and off label use: case report
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Off-label use and lack of efficacy: case report
Publicado: (2022)

COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report
por: Shimada, Ayako, et al.
Publicado: (2022)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

REMDESIVIR-ASSOCIATED ASYMPTOMATIC BRADYCARDIA IN AN ICU PATIENT ON DEXAMETHASONE FOR COVID-19
por: HAIDER, MOBEEN, et al.
Publicado: (2022)

SUN-422 Panhypopituitarism Secondary to Pituitary Macroadenoma with Optic Chiasm Compression and Possible Apoplexy
por: Petrenko, Olesya, et al.
Publicado: (2019)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

Mycobacterium fortuitum ventriculoperitoneal shunt infection in an immunocompromised patient: A case report
por: Lattanzio, Natalia, et al.
Publicado: (2020)

507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study
por: Dea, Lauren, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

Idiopathic Granulomatous Mastitis Presenting in a Patient With Hypothyroidism and Recent Hospitalization for Myxedema Coma: A Rare Case Report and Review of Literature
por: Bell, Stephen, et al.
Publicado: (2020)

Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial
por: Mohiuddin Chowdhury, Abu Taiub Mohammed, et al.
Publicado: (2022)

Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
por: Sodani, Pietro, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

1367. COVID-19 Patients Expressed Distinct Clinical Trait Signatures at Index Hospitalizations Across the Four SARS-CoV-2 Pandemic Waves in Florida
por: Motie, Ian, et al.
Publicado: (2023)

Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
Publicado: (2022)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia
por: Bell, Stephen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ibua84no67rjl8mfq68cti3prf